Good read, don't remember running across it before
Post# of 30028
Posted On: 08/11/2015 5:39:10 PM
Good read, don't remember running across it before.
http://www.kaloramainformation.com/article/20...kets-First
"The current state of AD biomarker research and significant remaining needs for AD assay development in drug development will stall the emergence of a larger clinical market for AD diagnostics. Companies such as Amarantus and proteomics suppliers are best served targeting the IUO or research assay market currently valued at $150 million. The potential multi-billion market in clinical AD diagnostics is tied to companion diagnostics (CDx) developments, or the advancement of AD therapeutics. Oncology represents the overwhelming majority of the current global CDx market, with neurological diseases not expected to represent any more than 2% of the CDx market through 2018."
http://www.kaloramainformation.com/article/20...kets-First
"The current state of AD biomarker research and significant remaining needs for AD assay development in drug development will stall the emergence of a larger clinical market for AD diagnostics. Companies such as Amarantus and proteomics suppliers are best served targeting the IUO or research assay market currently valued at $150 million. The potential multi-billion market in clinical AD diagnostics is tied to companion diagnostics (CDx) developments, or the advancement of AD therapeutics. Oncology represents the overwhelming majority of the current global CDx market, with neurological diseases not expected to represent any more than 2% of the CDx market through 2018."
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼